SCHEMBL7181776

SCHEMBL7181776

CCCN(CCC)c1cc(N2CCCN(C)CC2)ccc1S(=O)(=O)c1cc(F)cc(F)c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 10/20 0.40
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
HTR2C P28335 2/20 0.38
HTR7 P34969 2/20 0.38
HTR1A P08908 1/20 0.38
HTR2A P28223 1/20 0.38
DRD3 P35462 1/20 0.38
CHKA P35790 1/20 0.36
NTRK1 P04629 2/20 0.36
RORC P51449 1/20 0.35
DRD2 P14416 1/20 0.35
HTR2B P41595 1/20 0.35
FGFR4 P22455 1/20 0.35
NCF1 P14598 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7176613 0.96 HTR6 (0.43) HTR6POLBKMT2AHTR2CHTR7
SCHEMBL6744528 0.92 HTR6 (0.47) HTR6POLBKMT2AHTR2CHTR7
SCHEMBL6745801 0.92 HTR6 (0.44) HTR6POLBKMT2AHTR2CHTR7
SCHEMBL6747459 0.91 HTR6 (0.50) HTR6POLBKMT2AHTR2CHTR7
SCHEMBL6745771 0.89 HTR6 (0.40) HTR6POLBKMT2AHTR2CHTR7
SCHEMBL6746245 0.88 LMNA (0.39) HTR6POLBHTR2CHTR7HTR1A
SCHEMBL6742455 0.88 HTR6 (0.52) HTR6HTR2CHTR7HTR1AHTR2A
SCHEMBL6745662 0.88 HTR6 (0.50) HTR6POLBKMT2AHTR2CHTR7
SCHEMBL6744953 0.87 HTR6 (0.47) HTR6POLBKMT2AHTR2CHTR7
SCHEMBL6744973 0.87 HTR6 (0.53) HTR6POLBKMT2AHTR2CHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579870-B2 5-(1,4-diazepan-1-yl)-2-((3 -fluorophenyl)sulfonyl)phenylamine for example; treatment of diseases or disorders of the central nervous system; modulation of serotonin (5-HT) activity PHARMACIA & UPJOHN COMPANY 2003-06-17 US claimed
US-6579870-B2 5-(1,4-diazepan-1-yl)-2-((3 -fluorophenyl)sulfonyl)phenylamine for example; treatment of diseases or disorders of the central nervous system; modulation of serotonin (5-HT) activity PHARMACIA & UPJOHN COMPANY 2003-06-17 US disclosed
US-20020037892-A1 Bis-arylsulfones PHARMACIA & UPJOHN COMPANY 2002-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037892-A1 Bis-arylsulfones PMP22, ARSA, CLN6 HTR6 35/4885POLB 3539/4885KMT2A 3090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.